Dr. Wungki Park leads a trial that uses a monoclonal antibody to target a protein that is common in pancreatic cancer.
Two clinical trials in the Lustgarten Foundation’s Clinical Accelerator are testing different combinations of immunotherapy.
A clinical trial tests an investigational drug, immunotherapy, and radiation in combination against advanced pancreatic cancer.
Researchers are testing a PARP inhibitor that is effective for cancers in pancreatic cancer patients with DNA repair mutations.
Dr. Tanios Bekaii-Saab reports on the disappointing results of a trial combining an angiogenesis inhibitor and mFOLFIRINOX.
Dr. Allyson Ocean explains the concept behind a novel second-line treatment being tested for metastatic pancreatic cancer.
An investigational drug is being used in an expanded access trial for advanced pancreatic and other cancer patients with specific genetic changes.
A clinical trial for patients with metastatic pancreatic cancer uses the new drug SM-88 in combination with other agents, to attack the tumor metabolism.
Scientists are testing a new drug that is an antagonist of stress hormone receptors, in combination with nab-paclitaxel, for advanced pancreatic cancer.